Charted
Wednesday, Nov. 18, 2026The business of health, by the numbers
Live trackersDeal tracker $7.07B raisedFDA clearances 293 510(k)s in OctoberForm D raises $839M in 30 daysNew trials 266 Phase 2/3 in 30 days
Deals·SOFIE Biosciences

GE HealthCare agrees to pay $945 million for SOFIE's network of PET tracer plants

SOFIE Biosciences runs 15 U.S. manufacturing sites with 21 cyclotrons and already makes GE HealthCare's Flyrcado tracer. GE HealthCare is buying it from Trilantic North America in an all-cash deal.

From a GE HealthCare announcement published Oct. 5, 2026, and MedTech Dive coverage the same day
A worker at a SOFIE Biosciences radiopharmaceutical production site.
A worker at a SOFIE Biosciences radiopharmaceutical production site.Courtesy of GE HealthCare
Value
$945M
Type
Acquisition
Target
SOFIE Biosciences
Buyer
GE HealthCare
Sector
Diagnostics
Announced
Oct. 5, 2026

PET imaging agents labeled with fluorine-18 lose half their radioactivity every 110 minutes, which turns making and delivering them into a race against the clock. On Oct. 5, GE HealthCare agreed to pay $945 million in cash for SOFIE Biosciences, a U.S. contract manufacturer that runs that race for radiopharmaceutical companies.

GE HealthCare is buying SOFIE from Trilantic North America. SOFIE operates 15 contract manufacturing sites with 21 cyclotrons across the U.S., plus a site that develops and manufactures theranostics, according to GE HealthCare. It already produces GE HealthCare's Flyrcado (flurpiridaz F18 injection), a PET imaging agent.

Why it matters: GE HealthCare already makes and sells PET imaging agents. This deal would give it a U.S. network of contract plants in what the company calls the time-critical "final mile" of supply. Because SOFIE will keep making tracers for other radiopharmaceutical companies, the deal would also let GE HealthCare's PDx business take part in growth outside its own product portfolio, the company said.

The imaging agents sold by GE HealthCare's Pharmaceutical Diagnostics segment, known as PDx, were used in 140 million procedures in 2025, the company said. SOFIE will join PDx at closing, which GE HealthCare expects in the first half of 2027, subject to regulatory approvals and other conditions.

What GE HealthCare gets

GE HealthCare's case for the deal centers on that clock. The company said PET contract manufacturers like SOFIE are key to getting both current and pipeline products to patients on time. BTIG analyst Ryan Zimmerman made a similar point in a note to clients, saying such products need time-sensitive production and distribution, MedTech Dive reported.

The deal also brings U.S. rights to FAPI-74, a fibroblast activation protein inhibitor PET tracer that SOFIE has in Phase III development, according to GE HealthCare's announcement and MedTech Dive. GE HealthCare already held the rights outside the U.S. The company said about 20 PET radiotracers and more than 30 radiotherapeutics are in development across the industry.

After closing, SOFIE will run as a stand-alone manufacturing partner and keep supplying its current customers, including with other companies' radiopharmaceuticals, GE HealthCare said. GE HealthCare, in turn, plans to keep using its other U.S. contract manufacturers for its own F18 products alongside SOFIE.

Kevin O'Neill, president and chief executive of the PDx segment, said the business "enables us to participate across the radiopharmaceutical value stream." Patrick Phelps, SOFIE's co-founder and chief executive, pointed to rising demand for F18 products and growing pipelines of new radiopharmaceutical diagnostics and therapeutics.

The numbers, and what is missing

GE HealthCare expects SOFIE to grow at a low-double-digit rate under its ownership. It said the deal will lift its revenue growth, its adjusted margin on earnings before interest and taxes, and its adjusted earnings per share in its first full year owning SOFIE.

The company did not disclose SOFIE's revenue or profit, so the $945 million price cannot be measured against the business's sales. It also did not say how much of SOFIE's output goes to customers other than GE HealthCare.

Zimmerman wrote that the extra production and delivery capacity could ease bottlenecks in the adoption of radiopharmaceuticals, MedTech Dive reported. BofA Securities, Consello Financial and Solomon Partners Securities advised GE HealthCare.

Between now and the expected close in the first half of 2027, the deal needs regulatory approvals. After that, the pipeline item to watch is FAPI-74, the Phase III tracer to which GE HealthCare would then hold rights both in the U.S. and abroad.

Sara Montes de Oca is the Editor in Chief of Charted. She previously worked as a correspondent and producer in Washington, D.C., covering business, finance, and politics. Drafted with automated tools from the sources listed with this story and checked against them before publishing. How we report.

More Deals

More
Newsletter

Charted Daily

The day's deals, FDA decisions and policy moves, by the numbers. Free. Sign up now to get the first edition.

No spam. Unsubscribe any time.